Assessment of Potential Interactions Between Cocaine and Tolcapone - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: April 5, 2002
Last updated: February 8, 2007
Last verified: August 2003
The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone.
Primary Purpose: Treatment
||Assessment of Potential Interactions Between Intravenous Cocaine and Tolcapone
Primary Outcome Measures:
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
Double-blind, inpatient study by screening responses to cocaine infusions of 20 and 40 mg i.v. subjects into 1 of 2 treatment groups to assess potential interactions between i.v. cocaine infusion and treatment with tolcapone.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Volunteers dependent on cocaine and are non-treatment seeking; between 18-45 yrs of age; DSM-4 criteria for cocaine abuse or dependence
Additional criteria available during screening at the site
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033059
|UCLA Integrated Substance Abuse Program
|Los Angeles, California, United States, 90024 |
||Thomas Newton, M.D.
||National Institute on Drug Abuse (NIDA)
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 5, 2002
||February 8, 2007
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action